Grifols Announces the Completion of its Acquisition of Talecris and the Listing of its ADSs on NASDAQ
BARCELONA, Spain, June 3, 2011 /PRNewswire/ -- Grifols, S.A. (NASDAQ: GRFS) ("Grifols") a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that on June 1, 2011, Grifols completed its acquisition of Talecris Biotherapeutics Holdings Corp. ("Talecris"). In partial consideration for their shares, Talecris shareholders received Grifols non-voting shares that trade in the U.S. as Grifols ADSs. These new Grifols ADSs are listed on the NASDAQ Stock Exchange under the symbol "GRFS."
Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Stock Exchange ("Mercado Continuo") and is part of the Ibex-35 since 2008. After the recent purchase of Talecris, it is now the third company worldwide in the hemoderivative sector, with a balanced and diversified range of products. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to the ongoing investment plans. In terms of raw materials, Grifols is the world leader in plasma collection. Almost 150 plasmapheresis centers in the United States ensure plasma supply. In terms of fractionation, its several plants in Spain and the United States will allow the company to respond to the growing market demand. Grifols' sustained growth will be supported by a strong presence in the United States, Canada and Europe, where upcoming sales will represent 53%, 7% and 26%, respectively.
The facts and figures contained in this report which do not refer to historical data are "projections and forward-looking statements". The words and expressions like "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "try to achieve", "estimate", "future" and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.
More by this Source
Grifols va acquérir les activités diagnostiques de Novartis pour 1 675 millions de dollars
Nov 12, 2013, 08:08 ET
Grifols to acquire a Novartis diagnostics business unit for US$1,675 million
Nov 11, 2013, 02:18 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.